Bone metastases are very common in patients with prostate, breast, lung, kidney and thyroid cancer. Bone pain caused by bone metastases reduces the patient’s quality of life significantly, and patients often choose radiopharmaceuticals to relieve pain and improve their quality of life. Hydroxyethyl Dehyde diphosphonate (HEDP) is used to relieve the severe pain of bone metastases in cancer patients. After labeling with rhenium-188 this theranostic radiopharmaceutical kit is capable of relieving this type of pain and increasing the patient’s quality of life. Due to being a gamma emitter, rhenium-188 can be used for the purpose of treatment follow-up.